193 related articles for article (PubMed ID: 30361380)
21.
Price EW; Carnazza KE; Carlin SD; Cho A; Edwards KJ; Sevak KK; Glaser JM; de Stanchina E; Janjigian YY; Lewis JS
J Nucl Med; 2017 Sep; 58(9):1386-1394. PubMed ID: 28280216
[TBL] [Abstract][Full Text] [Related]
22. Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives.
Bartolazzi A; Sciacchitano S; D'Alessandria C
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29393868
[TBL] [Abstract][Full Text] [Related]
23. Recovery of NIS expression in thyroid cancer cells by overexpression of Pax8 gene.
Presta I; Arturi F; Ferretti E; Mattei T; Scarpelli D; Tosi E; Scipioni A; Celano M; Gulino A; Filetti S; Russo D
BMC Cancer; 2005 Jul; 5():80. PubMed ID: 16029487
[TBL] [Abstract][Full Text] [Related]
24. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
Mitrofanova E; Unfer R; Vahanian N; Link C
Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
[TBL] [Abstract][Full Text] [Related]
25. Association of low sodium-iodide symporter messenger ribonucleic acid expression in malignant thyroid nodules with increased intracellular protein staining.
Sodré AK; Rubio IG; Galrão AL; Knobel M; Tomimori EK; Alves VA; Kanamura CT; Buchpiguel CA; Watanabe T; Friguglietti CU; Kulcsar MA; Medeiros-Neto G; Camargo RY
J Clin Endocrinol Metab; 2008 Oct; 93(10):4141-5. PubMed ID: 18628528
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
[TBL] [Abstract][Full Text] [Related]
27. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
28. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
29. Low Elasticity of Thyroid Nodules on Ultrasound Elastography Is Correlated with Malignancy, Degree of Fibrosis, and High Expression of Galectin-3 and Fibronectin-1.
Rago T; Scutari M; Loiacono V; Santini F; Tonacchera M; Torregrossa L; Giannini R; Borrelli N; Proietti A; Basolo F; Miccoli P; Piaggi P; Latrofa F; Vitti P
Thyroid; 2017 Jan; 27(1):103-110. PubMed ID: 27809694
[TBL] [Abstract][Full Text] [Related]
30. Immuno-PET of undifferentiated thyroid carcinoma with radioiodine-labelled antibody cMAb U36: application to antibody tumour uptake studies.
Fortin MA; Salnikov AV; Nestor M; Heldin NE; Rubin K; Lundqvist H
Eur J Nucl Med Mol Imaging; 2007 Sep; 34(9):1376-87. PubMed ID: 17277931
[TBL] [Abstract][Full Text] [Related]
31. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
[TBL] [Abstract][Full Text] [Related]
32. Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3.
Bartolazzi A; D'Alessandria C; Parisella MG; Signore A; Del Prete F; Lavra L; Braesch-Andersen S; Massari R; Trotta C; Soluri A; Sciacchitano S; Scopinaro F
PLoS One; 2008; 3(11):e3768. PubMed ID: 19020658
[TBL] [Abstract][Full Text] [Related]
33. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
[TBL] [Abstract][Full Text] [Related]
34. Initial Clinical Investigation of [18F]Tetrafluoroborate PET/CT in Comparison to [124I]Iodine PET/CT for Imaging Thyroid Cancer.
Samnick S; Al-Momani E; Schmid JS; Mottok A; Buck AK; Lapa C
Clin Nucl Med; 2018 Mar; 43(3):162-167. PubMed ID: 29356744
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Evaluation of the Hsp70 Peptide Tracer TPP-PEG
Stangl S; Tei L; De Rose F; Reder S; Martinelli J; Sievert W; Shevtsov M; Öllinger R; Rad R; Schwaiger M; D'Alessandria C; Multhoff G
Cancer Res; 2018 Nov; 78(21):6268-6281. PubMed ID: 30228173
[TBL] [Abstract][Full Text] [Related]
36. Combining transfer of TTF-1 and Pax-8 gene: a potential strategy to promote radioiodine therapy of thyroid carcinoma.
Mu D; Huang R; Li S; Ma X; Lou C; Kuang A
Cancer Gene Ther; 2012 Jun; 19(6):402-11. PubMed ID: 22498723
[TBL] [Abstract][Full Text] [Related]
37. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.
Sui X; Sui Y; Wang Y
Mol Med Rep; 2018 Jun; 17(6):7521-7528. PubMed ID: 29620212
[TBL] [Abstract][Full Text] [Related]
38. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
Than TH; Swethadri GK; Wong J; Ahmad T; Jamil D; Maganlal RK; Hamdi MM; Abdullah MS
Singapore Med J; 2008 Apr; 49(4):333-8. PubMed ID: 18418527
[TBL] [Abstract][Full Text] [Related]
39. Runt-Related Transcription Factor 2 (Runx2) Is Responsible for Galectin-3 Overexpression in Human Thyroid Carcinoma.
Kaptan E; Sancar Bas S; Sancakli A; Aktas HG; Bayrak BB; Yanardag R; Bolkent S
J Cell Biochem; 2017 Nov; 118(11):3911-3919. PubMed ID: 28390192
[TBL] [Abstract][Full Text] [Related]
40. Sodium iodide symporter: its role in nuclear medicine.
Chung JK
J Nucl Med; 2002 Sep; 43(9):1188-200. PubMed ID: 12215558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
